ABSTRACT
INTRODUCTION
Traditionally, atherosclerotic disease is considered a typical middleage disease. The most common heart disease is coronary artery disease (CAD), which often appears as a heart attack (1) .
The atherosclerotic process starts decades before the appearance of clinical symptoms (myocardial infarction, cerebral vascular accident and peripheral vascular disease). The progression and the severity of the atherosclerotic process are related to the presence, number, magnitude and duration of a series of risk factors (2) . Cardiovascular disease is the leading cause of mortality, not only in the Western world, but also in developing countries. Coronary artery disease is a global health concern today, with limited treatment options available to address that disorder. Extensive efforts have been devoted to molecular therapies to enhance perfusion and function of the ischemic myocardium (3) . Insulin-like growth factor I (IGF-I) is a peptide hormone that shares sequence homology with insulin and has a fundamental role in somatic growth and cellular differentiation, metabolism and survival (4) . IGF-1 is expressed, under GH (growth hormone) control, by the liver in an endocrine form or ubiquitously in a relevant 'paracrine/autocrine' fashion (5) . Besides the liver, important contributions to serum IGF-1 levels come from bone, vascular endothelium and exercising skeletal muscle (6) to give a total daily secretion of approx. 3−10 mg/day (7) . Daily IGF-1 serum preservation/tissue delivery is supervised by six different specific high-affinity binding proteins (IGFBP-1to IGFBP-6), synthesized mainly by the liver, which can bind IGF-1 in biological fluids, regulating its movement between intravascular and extravascular compartments, increasing its half-life, and managing IGF delivery to tissues by fine-tuning its concentrations in the interstitial fluid and its affinity for receptors (8) . The majority of IGFs in the circulation are bound to IGF binding proteins, of which IGF binding protein 3 (IGFBP-3) is the most predominant, carrying > 80% of circulating IGF-I. But, although IGFBP-3 is an important regulator of the bioactivity of IGF-I, there is evidence to suggest that IGFBP-3 possesses functions independent of its role as an IGF-I carrier protein (9) . It has been suggested that circulating IGF-I is involved in the pathophysiological processes underlying coronary artery disease (CAD 
MATERIALS & METHODS

RESULTS
The current study aimed to determine the role of IGF-1 and IGFBP-3 in patients with CAD compared to healthy controls. It included 62 patients presented with CAD attending Suez Canal University Hospital in Ismailia and 30 apparently healthy controls. The mean age of CAD patients was 54.56±8.9 years, with a range of 36 -75 years. Controls´ age ranged 36-73 years, with a mean of 49.6 ± 10.2 years.
There was no significant difference between patients and control groups regarding to smoking, hypertension and diabetes mellitus (P>0.05). Coronary artery disease was more frequent among males compared to females (67.7%, versus 32.3% respectively). Both groups were matched for age and sex with no significant difference between patients and control regarding to smoking, hypertension and diabetes mellitus (pvalue >0.05) as shown in table (1). Table ( 2) showed that TC, LDLc, and TAG were significantly higher, while HDLc was significantly lower in patients than controls. Table ( 3) showed that the mean IGF-1 was significantly higher among controls group (212.5 ± 109.1ng/ml) compared to patients group (129.5 ± 66.2 ng/ml) (p= 0.001). Moreover, the mean IGFBP-3 was higher among controls group (6.4 ± 2.3ng/ml) than patients group (4.4 ± 1.6ng/ml), with significant difference (p= 0.001). Table ( 4) showed severity of the disease where 48.4% of patients had 3 stenosed vessels, 21% had 2 stenosed vessels while 30.6% had one vessel affected. The mean percent of stenosis was 74.7 ± 14.2 %. Table (5) showed the correlation between the means of IGF-1 and IGFBP-3 in the patients group and the severity of disease. IGF-1 and IGFBP-3 were lower in the group of three affected vessels but there was no significant correlation between both parameters and severity of the disease. ) demonstrated that the low IGF-1 and high IGFPP-3 predicted increased risk of ischemic heart disease in a case control study which was conducted in a large prospective study on cardiovascular epidemiology (26) . The present study showed no relation between IGF-1, IGFBP-3 and severity of IHD in the study group.
Schuler-Lüttmann et al. (2000)
examined the associations of IGF-1 and IGFBP-3 with three coronary scores: a vessel score, a stenosis score, and an extent score and found IGFBP-3 to be significantly inversely associated with all three scores. They also reported that IGF-1 was inversely associated with arteriosclerosis in unadjusted analysis, but in multivariate analysis the association between vessel score and IGF-1 became positive and marginally significant and the associations for stenosis score and extent score became non-significant 
